In line with its well-known variability in clinical behaviors, breast cancer is a highly heterogeneous disease characterized by distinct molecular subtypes, typically assessed in the routine setting through the expression of HER2, estrogen receptor (ER), and progesterone receptor (PR) [126]. This evidence concerns the gene PGR and breast carcinoma.